By Denny Jacob
Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.
The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year.
Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs.
Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 17, 2025 08:57 ET (12:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。